Takeda Pharmaceutical Co (FRA:TKD) Cyclically Adjusted FCF per Share: €1.98 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:TKD Takeda Pharmaceutical Co Ltd FRA:TKD
65 GF Score
Price €29.74
GF Value €24.32
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co Cyclically Adjusted FCF per Share?

Takeda Pharmaceutical Co FRA:TKD +0.10% 65 Cyclically Adjusted FCF per Share is €1.98 as of Mar. 2026. GuruFocus rates FRA:TKD with a GF Score™ of 65/100 and a GF Value™ of €24.32 (Modestly Overvalued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Takeda Pharmaceutical Co's adjusted free cash flow per share for the three months ended in Mar. 2026 was €0.035. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €1.98 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Takeda Pharmaceutical Co's average Cyclically Adjusted FCF Growth Rate was 17.30% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 12.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Takeda Pharmaceutical Co was 13.20% per year. The lowest was 3.20% per year. And the median was 9.50% per year.

As of today (2026-07-22), Takeda Pharmaceutical Co's current stock price is €29.74. Takeda Pharmaceutical Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €1.98. Takeda Pharmaceutical Co's Cyclically Adjusted Price-to-FCF of today is 15.02.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Takeda Pharmaceutical Co was 39.61. The lowest was 12.65. And the median was 18.27.


Takeda Pharmaceutical Co  (FRA:TKD) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Takeda Pharmaceutical Co's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=29.74/1.98
=15.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Takeda Pharmaceutical Co was 39.61. The lowest was 12.65. And the median was 18.27.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Takeda Pharmaceutical Co Cyclically Adjusted FCF per Share Related Terms


Takeda Pharmaceutical Co Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Takeda Pharmaceutical Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co Cyclically Adjusted FCF per Share Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.81 1.74 1.62 1.86 1.98

Takeda Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.86 1.85 1.87 1.78 1.98

FRA:TKD vs ZTS, UTHR: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Cyclically Adjusted Price-to-FCF falls into.


FRA:TKD
65GF Score
Takeda Pharmaceutical Co Ltd FRA:TKD
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takeda Pharmaceutical Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Takeda Pharmaceutical Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.035/112.7000*112.7000
=0.035

Current CPI (Mar. 2026) = 112.7000.

Takeda Pharmaceutical Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.391 98.100 0.449
201609 0.427 98.000 0.491
201612 -0.115 98.400 -0.132
201703 0.902 98.100 1.036
201706 0.480 98.500 0.549
201709 0.355 98.800 0.405
201712 0.621 99.400 0.704
201803 0.975 99.200 1.108
201806 0.052 99.200 0.059
201809 0.526 99.900 0.593
201812 0.616 99.700 0.696
201903 0.374 99.700 0.423
201906 0.408 99.800 0.461
201909 1.010 100.100 1.137
201912 0.343 100.500 0.385
202003 0.655 100.300 0.736
202006 0.555 99.900 0.626
202009 1.052 99.900 1.187
202012 0.876 99.300 0.994
202103 1.418 99.900 1.600
202106 0.604 99.500 0.684
202109 0.926 100.100 1.043
202112 1.476 100.100 1.662
202203 1.573 101.100 1.753
202206 -0.064 101.800 -0.071
202209 0.813 103.100 0.889
202212 1.460 104.100 1.581
202303 -0.663 104.400 -0.716
202306 -0.738 105.200 -0.791
202309 0.522 106.200 0.554
202312 0.273 106.800 0.288
202403 0.830 107.200 0.873
202406 0.062 108.200 0.065
202409 0.800 108.900 0.828
202412 1.261 110.700 1.284
202503 0.498 111.100 0.505
202506 0.530 111.700 0.535
202509 1.169 112.000 1.176
202512 0.515 113.000 0.514
202603 0.035 112.700 0.035

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €1.98 mean?
Takeda Pharmaceutical Co (FRA:TKD) has a Cyclically Adjusted FCF per Share of €1.98 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Takeda Pharmaceutical Co and its competitors.
Is Takeda Pharmaceutical Co's Cyclically Adjusted FCF per Share too high?
Takeda Pharmaceutical Co's current Cyclically Adjusted FCF per Share is €1.98. Overall, Takeda Pharmaceutical Co has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Cyclically Adjusted FCF per Share compare to ZTS and UTHR?
Takeda Pharmaceutical Co's Cyclically Adjusted FCF per Share of €1.98 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current Cyclically Adjusted FCF per Share is €1.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (FRA:TKD) is currently considered Modestly Overvalued. The stock's GF Value™ is €24.32, compared to a current price of €29.74 — trading 22.3% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €1.98. Takeda Pharmaceutical Co's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Takeda Pharmaceutical Co (FRA:TKD), the current Cyclically Adjusted FCF per Share is €1.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takeda Pharmaceutical Co (FRA:TKD) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of €29.74 is trading 22.3% above its estimated GF Value™ of €24.32. GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for FRA:TKD:

  • Cyclically Adjusted FCF per Share: €1.98
  • GF Value™: €24.32 vs. price of €29.74 (22.3% above fair value)
  • GF Score™: 65/100 with 10 warning signs

No single metric tells the full story. See the FRA:TKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
65GF Score

Get the complete analysis for FRA:TKD

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.74
Price
€24.32
GF Value